Open AccessErratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Author(s) -
Linda A. Gallo,
Micheal Ward,
Amelia K. Fotheringham,
Aowen Zhuang,
Danielle J. Borg,
Nicole Flemming,
Ben M. Harvie,
Toni L. Kinneally,
Shang-Ming Yeh,
Domenica A. McCarthy,
Hermann Koepsell,
Volker Vallon,
Carol A. Pollock,
Usha Panchapakesan,
Josephine M. Forbes
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep28124
Subject(s) - empagliflozin , albuminuria , medicine , diabetes mellitus , medical research , family medicine , urology , type 2 diabetes , political science , endocrinology , pathology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom